Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 08:10PM GMT
Michael Guba

Hi. My name is Mike Guba. I'm Citi's U.S. health care sector specialist. And today, I have the pleasure of welcoming Greg Glenn, Novavax' President of R&D; as well as John Trizzino, Executive Vice President and Chief Commercial Officer and Chief Business Officer for Novavax.

Greg, John, thank you very much for joining us.

Questions & Answers

Michael Guba

Just to kick it off, right, I've been hopping right into it because it's been a long day for just about everyone, so I think we should just get straight to the content. So starting off at a high level, can you kind of give us a brief state of the union on where your COVID vaccine program stands as of now? Has there been any update since 2Q that you'd like to share to the market? And any kind of just broad, broad statements there to start.

Gregory M. Glenn
Novavax, Inc. - President of Research & Development

Yes. So thanks, and thanks for having us, Mike. We're at a great place with our vaccine. We did a number of trials in vaccines. You do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot